Has Dipakkumar Pandya, MD received payments from drug or device companies?

Yes. Drug and device makers reported $85,338 in general payments to Dipakkumar Pandya, MD across 1,254 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dipakkumar Pandya, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dipakkumar Pandya, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dipakkumar Pandya, MD

Neurology · Annandale, NJNPI 1265486294

Payments from drug & device makers

$85,338in general payments, 2019–2025

Across 1,254 payments — averaging $68.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$68K
Sunovion Pharmaceuticals Inc.$4K
Biogen$1K
Novartis$1K
UCB, Inc.$971
Teva Pharmaceuticals USA, Inc.$812
plus $9K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	280	$67,803
Sunovion Pharmaceuticals Inc.	16	$4,020
Biogen	79	$1,329
Novartis	89	$1,124
UCB, Inc.	65	$971
Teva Pharmaceuticals USA, Inc.	75	$812
Lilly USA, LLC	49	$686
Amneal Pharmaceuticals LLC	53	$662
Eisai Inc.	38	$507
Lundbeck LLC	36	$465
EMD Serono, Inc.	35	$452
Pfizer	27	$375
AstraZeneca(2 entities)	20	$321
Supernus Pharmaceuticals, Inc.	27	$314
Jazz Pharmaceuticals Inc.	16	$307
Amgen(2 entities)	23	$306
Argenx US, Inc.	19	$303
Bristol Myers Squibb	22	$298
Genentech USA, Inc.	18	$283
SK Life Science, Inc.	16	$272
CSL Behring	17	$270
Kyowa Kirin, Inc.	18	$256
Johnson & Johnson(2 entities)	19	$222
Boston Scientific	5	$168
Adamas Pharmaceuticals, Inc.	10	$144
Acadia Pharmaceuticals Inc	16	$144
Neurocrine Biosciences, Inc.	7	$120
Scilex Pharmaceuticals Inc.	8	$118
Biohaven Pharmaceutical Holding Company Ltd.	9	$118
Neurelis, Inc.	8	$117
TG Therapeutics, Inc.	6	$117
Acorda Therapeutics, Inc	8	$115
Otsuka America Pharmaceutical, Inc.	7	$114
Sanofi	8	$104
ANI Pharmaceuticals, Inc.	6	$98
Grifols USA, LLC	6	$93
GE HealthCare	6	$84
Mallinckrodt Enterprises LLC	6	$84
Amylyx Pharmaceuticals, Inc.	5	$83
MDD US Operations, LLC	5	$74
Azurity Pharmaceuticals, Inc.	4	$68
Avion Pharmaceuticals	4	$68
Akcea Therapeutics, Inc.	4	$61
Aquestive Therapeutics, Inc.	4	$58
Harmony Biosciences LLC	3	$56
Sumitomo Pharma America, Inc.	5	$56
Impel Pharmaceuticals Inc.	3	$52
Takeda Pharmaceuticals U.S.A., Inc.	3	$48
Axsome Therapeutics, Inc.	3	$44
Abbott	1	$38
Philips North America LLC	2	$37
Greenwich Biosciences, Inc.	2	$36
Inspire Medical Systems, Inc.	2	$33
Alnylam Pharmaceuticals Inc.	2	$32
Vanda Pharmaceuticals Inc.	2	$31
Merz Pharmaceuticals, LLC	2	$29
Promius Pharma LLC	2	$29
Avanir Pharmaceuticals, Inc.	2	$28
Aprecia Pharmaceuticals, LLC	2	$27
Insightec,inc	2	$25

How this compares

$85,338 in reported general payments places this provider in the 90th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey →

Medicare billing

Part B allowed, 2024

$1,491,882

Medicare patients

659

Services billed

60,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Annandale

Mary Ann PiconeTeaneck$2.8M
Steven BromleyAudubon$1.7M
David DuncanNeptune$1.5M
Lana Zhovtis RyersonNeptune$1.3M
Amos KatzEatontown$1.2M
Fiona GuptaOradell$1.1M
Andrew SylvesterBridgewater$1.1M
Machteld HillenNewark$999K
Matthew TremblayLivingston$812K
Noah GilsonWest Long Branch$800K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →